Published in PLoS One on December 13, 2011
Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol Heart Circ Physiol (2015) 2.16
Estrogen inhibits mast cell chymase release to prevent pressure overload-induced adverse cardiac remodeling. Hypertension (2014) 1.50
Update on the Angiotensin converting enzyme 2-Angiotensin (1-7)-MAS receptor axis: fetal programing, sex differences, and intracellular pathways. Front Endocrinol (Lausanne) (2014) 1.22
Nonclassical renin-angiotensin system and renal function. Compr Physiol (2012) 1.02
Uptake and metabolism of the novel peptide angiotensin-(1-12) by neonatal cardiac myocytes. PLoS One (2011) 1.00
Characterization of the cardiac renin angiotensin system in oophorectomized and estrogen-replete mRen2.Lewis rats. PLoS One (2013) 0.95
International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. Pharmacol Rev (2015) 0.94
An evolving story of angiotensin-II-forming pathways in rodents and humans. Clin Sci (Lond) (2014) 0.93
ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep (2014) 0.92
Chymase mediates angiotensin-(1-12) metabolism in normal human hearts. J Am Soc Hypertens (2013) 0.90
Divergent pathways for the angiotensin-(1-12) metabolism in the rat circulation and kidney. Peptides (2012) 0.90
Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension. Hypertension (2012) 0.86
Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate. Curr Hypertens Rep (2014) 0.83
Primacy of angiotensin converting enzyme in angiotensin-(1-12) metabolism. Am J Physiol Heart Circ Physiol (2013) 0.81
Expression of Cathepsins B, D, and G in Infantile Hemangioma. Front Surg (2015) 0.80
Cardiac angiotensin-(1-12) expression and systemic hypertension in rats expressing the human angiotensinogen gene. Am J Physiol Heart Circ Physiol (2016) 0.79
Intracrine angiotensin II functions originate from noncanonical pathways in the human heart. Am J Physiol Heart Circ Physiol (2016) 0.78
The multiple mechanistic faces of a pure volume overload: implications for therapy. Am J Med Sci (2014) 0.78
Angiotensin-[1-12] interacts with angiotensin type I receptors. Neuropharmacology (2013) 0.77
Increased fibroblast chymase production mediates procollagen autophagic digestion in volume overload. J Mol Cell Cardiol (2016) 0.77
Cardiac remodelling and RAS inhibition. Ther Adv Cardiovasc Dis (2016) 0.77
The never-ending story of angiotensin peptides: beyond angiotensin I and II. Circ Res (2013) 0.76
Angiotensin-converting enzyme inhibitor does not suppress renal angiotensin II levels in angiotensin I-infused rats. J Pharmacol Sci (2013) 0.75
Atlas of tissue renin-angiotensin-aldosterone system in human: A transcriptomic meta-analysis. Sci Rep (2015) 0.75
Expression of recombinant human mast cell chymase with Asn-linked glycans in glycoengineered Pichia pastoris. Protein Expr Purif (2014) 0.75
Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1-12) metabolizing enzyme. Biochem Biophys Res Commun (2016) 0.75
Chymase-dependent production of angiotensin II: an old enzyme in old hearts. Am J Physiol Heart Circ Physiol (2016) 0.75
Role of chymase in the local renin-angiotensin system in keloids: inhibition of chymase may be an effective therapeutic approach to treat keloids. Drug Des Devel Ther (2015) 0.75
Significance of angiotensin 1-7 coupling with MAS1 receptor and other GPCRs to the renin-angiotensin system: IUPHAR Review 22. Br J Pharmacol (2017) 0.75
The benefit of angiotensin AT1 receptor blockers for early treatment of hypertensive patients. Intern Emerg Med (2017) 0.75
Renin Angiotensin Aldosterone Inhibition in the Treatment of Cardiovascular Disease. Pharmacol Res (2017) 0.75
Physiology of local renin-angiotensin systems. Physiol Rev (2006) 5.77
Mapping the extended substrate binding site of cathepsin G and human leukocyte elastase. Studies with peptide substrates related to the alpha 1-protease inhibitor reactive site. J Biol Chem (1979) 2.66
Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem (1990) 2.41
Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol (2003) 2.20
Angiotensin II-forming pathways in normal and failing human hearts. Circ Res (1990) 1.97
Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. Cardiovasc Res (2009) 1.83
Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2-dependent processing of angiotensin II. Am J Physiol Renal Physiol (2006) 1.61
Chymase-dependent angiotensin II formation in human vascular tissue. Circulation (1999) 1.60
Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun (2006) 1.58
Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest (1993) 1.50
Chronic chymase inhibition preserves cardiac function after left ventricular repair in rats. Eur J Cardiothorac Surg (2007) 1.50
Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol Heart Circ Physiol (2008) 1.34
The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. Am J Physiol Renal Physiol (2010) 1.34
A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci (1993) 1.31
New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension (2009) 1.28
Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest (2010) 1.26
Nuclear angiotensin II type 2 (AT2) receptors are functionally linked to nitric oxide production. Am J Physiol Renal Physiol (2009) 1.26
Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats. Am J Physiol Heart Circ Physiol (2008) 1.20
Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther (2006) 1.19
Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol (2009) 1.18
Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from the human heart. J Biol Chem (1991) 1.13
Cloning of the gene and cDNA for human heart chymase. J Biol Chem (1991) 1.13
Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension (1998) 1.13
Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci (2006) 1.13
Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol (1997) 1.12
Catabolism of intact type VI collagen microfibrils: susceptibility to degradation by serine proteinases. Biochem Biophys Res Commun (1993) 1.10
Signaling by the angiotensin-converting enzyme. Circ Res (2006) 1.08
Influence of estrogen depletion and salt loading on renal angiotensinogen expression in the mRen(2).Lewis strain. Am J Physiol Renal Physiol (2010) 1.05
Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases. Curr Opin Cardiol (2002) 1.04
Angiotensin-(1-12) requires angiotensin converting enzyme and AT1 receptors for cardiovascular actions within the solitary tract nucleus. Am J Physiol Heart Circ Physiol (2010) 1.03
Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation. Am J Physiol (1995) 1.02
Chronic immunoneutralization of brain angiotensin-(1-12) lowers blood pressure in transgenic (mRen2)27 hypertensive rats. Am J Physiol Regul Integr Comp Physiol (2009) 1.01
New angiotensins. J Mol Med (Berl) (2008) 1.00
New approaches to blockade of the renin-angiotensin-aldosterone system: chymase as an important target to prevent organ damage. J Pharmacol Sci (2010) 1.00
Uptake and metabolism of the novel peptide angiotensin-(1-12) by neonatal cardiac myocytes. PLoS One (2011) 1.00
The hypothalamic arcuate nucleus: a new site of cardiovascular action of angiotensin-(1-12) and angiotensin II. Am J Physiol Heart Circ Physiol (2010) 0.99
Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. Am J Physiol Renal Physiol (2010) 0.96
Cardiovascular responses elicited by a new endogenous angiotensin in the nucleus tractus solitarius of the rat. Am J Physiol Heart Circ Physiol (2010) 0.90
Increased expression of the renin-angiotensin system and mast cell density but not of angiotensin-converting enzyme II in late stages of human heart failure. J Heart Lung Transplant (2006) 0.90
Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice. Atherosclerosis (2008) 0.89
Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. Arterioscler Thromb Vasc Biol (2002) 0.89
Characterization of chymase from human vascular tissues. Clin Chim Acta (1997) 0.87
Regional vascular response to ProAngiotensin-12 (PA12) through the rat arterial system. Peptides (2010) 0.85
Regulation of extravascular coagulation and fibrinolysis by heparin-dependent mast cell chymase. FASEB J (2001) 0.84
Formation of angiotensin II from tetradecapeptide renin substrate by angiotensin-converting enzyme. Biochem Pharmacol (1975) 0.84
Significance of chymase-dependent angiotensin II formation in the progression of human liver fibrosis. Hepatol Res (2007) 0.83
Angiotensinogen metabolism in rat aorta: robust formation of proangiotensin-12. J Physiol Pharmacol (2010) 0.82
Chymase: its pathophysiological roles and inhibitors. Curr Pharm Des (1998) 0.80
Changes of chymase, angiotensin converting enzyme and angiotensin II type 1 receptor expressions in the hamster heart during the development of heart failure. Chin Med J (Engl) (2005) 0.79
Angiotensin-converting enzyme inhibition augments the expression of rat elastase-2, an angiotensin II-forming enzyme. Am J Physiol Heart Circ Physiol (2011) 0.79
Use of angiotensin-converting enzyme inhibitors in patients with diabetes and coronary artery disease. Curr Probl Cardiol (2002) 0.77
New developments in our knowledge of the chemistry of renin. Fed Proc (1977) 0.76
Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature (2002) 5.02
Value of noninvasive hemodynamics to achieve blood pressure control in hypertensive subjects. Hypertension (2006) 2.31
Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats. Am J Hypertens (2013) 2.11
Central angiotensin-(1-7) improves vagal function independent of blood pressure in hypertensive (mRen2)27 rats. Hypertension (2012) 2.01
Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension (2004) 1.96
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation (2005) 1.92
Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol (2005) 1.92
Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol (2005) 1.85
ACE2 and ANG-(1-7) in the rat uterus during early and late gestation. Am J Physiol Regul Integr Comp Physiol (2007) 1.85
Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens (2004) 1.81
Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol (2005) 1.81
Major role for ACE-independent intrarenal ANG II formation in type II diabetes. Am J Physiol Renal Physiol (2009) 1.75
Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int (2005) 1.71
Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol (2007) 1.65
Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension (2003) 1.62
Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2-dependent processing of angiotensin II. Am J Physiol Renal Physiol (2006) 1.61
Adenovirus-mediated small-interference RNA for in vivo silencing of angiotensin AT1a receptors in mouse brain. Hypertension (2005) 1.60
Diabetes, hypertension, and dyslipidemia in Mexican Americans and non-Hispanic whites. Am J Prev Med (2006) 1.56
Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension (2009) 1.52
Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J Am Coll Cardiol (2004) 1.51
Differential expression of nuclear AT1 receptors and angiotensin II within the kidney of the male congenic mRen2. Lewis rat. Am J Physiol Renal Physiol (2006) 1.48
Impaired heart rate baroreflex in older rats: role of endogenous angiotensin-(1-7) at the nucleus tractus solitarii. Hypertension (2005) 1.45
Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology (2009) 1.42
Sex differences in circulating and renal angiotensins of hypertensive mRen(2). Lewis but not normotensive Lewis rats. Am J Physiol Heart Circ Physiol (2008) 1.41
Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am J Physiol Cell Physiol (2005) 1.40
Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab (2007) 1.36
Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol Heart Circ Physiol (2008) 1.34
The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. Am J Physiol Renal Physiol (2010) 1.34
Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab (2004) 1.33
NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension (2007) 1.32
Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat. Hypertension (2003) 1.32
Alterations in circulatory and renal angiotensin-converting enzyme and angiotensin-converting enzyme 2 in fetal programmed hypertension. Hypertension (2008) 1.30
Angiotensin-(1-7)-angiotensin-converting enzyme 2 attenuates reactive oxygen species formation to angiotensin II within the cell nucleus. Hypertension (2009) 1.30
Angiotensin-(1-7) in normal and preeclamptic pregnancy. Endocrine (2002) 1.30
Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res (2007) 1.28
Nuclear angiotensin II type 2 (AT2) receptors are functionally linked to nitric oxide production. Am J Physiol Renal Physiol (2009) 1.26
Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am J Physiol Regul Integr Comp Physiol (2011) 1.26
Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2.Lewis female rat. J Cardiovasc Pharmacol (2011) 1.24
Injections of angiotensin-converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce baroreceptor reflex sensitivity for heart rate control in rats. Exp Physiol (2008) 1.24
Salt loading produces severe renal hemodynamic dysfunction independent of arterial pressure in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol (2006) 1.22
Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology (2008) 1.21
Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats. Am J Physiol Heart Circ Physiol (2008) 1.20
MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol (2008) 1.20
Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol (2008) 1.20
Angiotensin-(1-7) and baroreflex function in nucleus tractus solitarii of (mRen2)27 transgenic rats. J Cardiovasc Pharmacol (2008) 1.20
The angiotensin II-AT1 receptor stimulates reactive oxygen species within the cell nucleus. Biochem Biophys Res Commun (2009) 1.19
Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol (2009) 1.18
Echocardiographic measurement of cardiac output in rats. Am J Physiol Heart Circ Physiol (2002) 1.17
Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab (2008) 1.15
Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br J Haematol (2004) 1.15
Growth hormone replacement attenuates diastolic dysfunction and cardiac angiotensin II expression in senescent rats. J Gerontol A Biol Sci Med Sci (2006) 1.13
Modulation of reflex function by endogenous angiotensins in older transgenic rats with low glial angiotensinogen. Hypertension (2008) 1.12
Nuclear angiotensin-(1-7) receptor is functionally coupled to the formation of nitric oxide. Am J Physiol Renal Physiol (2010) 1.11
Activation of local chorionic villi angiotensin II levels but not angiotensin (1-7) in preeclampsia. Hypertension (2008) 1.10
Attenuation of salt-induced cardiac remodeling and diastolic dysfunction by the GPER agonist G-1 in female mRen2.Lewis rats. PLoS One (2010) 1.10
Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation (2003) 1.09
Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev (2007) 1.08
Cardiac kallikrein-kinin system is upregulated in chronic volume overload and mediates an inflammatory induced collagen loss. PLoS One (2012) 1.08
The role of sodium in hypertension is more complex than simply elevating arterial pressure. Nat Clin Pract Cardiovasc Med (2004) 1.08
Diastolic dysfunction in hypertension. Curr Opin Cardiol (2002) 1.07
Glucocorticoid-induced fetal programming alters the functional complement of angiotensin receptor subtypes within the kidney. Hypertension (2011) 1.07
Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol (2008) 1.06
Estrogen receptor GPR30 reduces oxidative stress and proteinuria in the salt-sensitive female mRen2.Lewis rat. Hypertension (2011) 1.06
Novel aspects of the renal renin-angiotensin system: angiotensin-(1-7), ACE2 and blood pressure regulation. Contrib Nephrol (2004) 1.06
Growth, metabolism, and blood pressure disturbances during aging in transgenic rats with altered brain renin-angiotensin systems. Physiol Genomics (2005) 1.06
Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am J Physiol Lung Cell Mol Physiol (2009) 1.06
Influence of estrogen depletion and salt loading on renal angiotensinogen expression in the mRen(2).Lewis strain. Am J Physiol Renal Physiol (2010) 1.05
Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat. Kidney Int (2002) 1.05
Baroreceptor reflex regulation in anesthetized transgenic rats with low glia-derived angiotensinogen. Am J Physiol Heart Circ Physiol (2006) 1.05
Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol (2006) 1.05
Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol (2009) 1.04
Allelic variants of the human scavenger receptor class B type 1 and paraoxonase 1 on coronary heart disease: genotype-phenotype correlations. Arterioscler Thromb Vasc Biol (2005) 1.04
Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. Am J Physiol Heart Circ Physiol (2007) 1.04
Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol (2003) 1.03
Progressive diastolic dysfunction in the female mRen(2). Lewis rat: influence of salt and ovarian hormones. J Gerontol A Biol Sci Med Sci (2008) 1.03
Angiotensin-(1-12) requires angiotensin converting enzyme and AT1 receptors for cardiovascular actions within the solitary tract nucleus. Am J Physiol Heart Circ Physiol (2010) 1.03
Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. Am J Nephrol (2011) 1.03
Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat. Am J Nephrol (2009) 1.02
Chronic immunoneutralization of brain angiotensin-(1-12) lowers blood pressure in transgenic (mRen2)27 hypertensive rats. Am J Physiol Regul Integr Comp Physiol (2009) 1.01
Enhanced renal immunocytochemical expression of ANG-(1-7) and ACE2 during pregnancy. Hypertension (2003) 1.01
Differential regulation of circulating and renal ACE2 and ACE in hypertensive mRen2.Lewis rats with early-onset diabetes. Am J Physiol Renal Physiol (2012) 1.01
Uptake and metabolism of the novel peptide angiotensin-(1-12) by neonatal cardiac myocytes. PLoS One (2011) 1.00
Aging and the brain renin-angiotensin system: insights from studies in transgenic rats. Cleve Clin J Med (2007) 1.00
Angiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-gamma and catalase activities. Eur J Pharmacol (2010) 1.00